Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Habig is active.

Publication


Featured researches published by Michael Habig.


Molecular Pharmacology | 2008

Targeting Ceramide Metabolism with a Potent and Specific Ceramide Kinase Inhibitor

Christine Graf; Martin Klumpp; Michael Habig; Philipp Rovina; Andreas Billich; Thomas Baumruker; Berndt Oberhauser; Frédéric Bornancin

Ceramide kinase (CerK) produces the bioactive lipid ceramide-1-phosphate (C1P) and appears as a key enzyme for controlling ceramide levels. In this study, we discovered and characterized adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide (NVP-231), a potent, specific, and reversible CerK inhibitor that competitively inhibits binding of ceramide to CerK. NVP-231 is active in the low nanomolar range on purified as well as cellular CerK and abrogates phosphorylation of ceramide, resulting in decreased endogenous C1P levels. When combined with another ceramide metabolizing inhibitor, such as tamoxifen, NVP-231 synergistically increased ceramide levels and reduced cell growth. Therefore, NVP-231 represents a novel and promising compound for controlling ceramide metabolism that may provide insight into CerK physiological function.


Archives of Virology | 2006

E7 proteins from high- and low-risk human papillomaviruses bind to TGF-β-regulated Smad proteins and inhibit their transcriptional activity ∗

Michael Habig; Hans Smola; V. S. Dole; R. Derynck; Herbert Pfister; S. Smola-Hess

Summary.Human papillomaviruses (HPV) infect keratinocytes of skin and mucosa. Persistent infection can lead to the formation of benign tumors. In cases of high-risk HPV, such as HPV16 or 18, these may further progress to cancer. In order to support viral replication in suprabasal keratinocytes, the HPV E7 protein employs various strategies to keep keratinocytes in cycle and counteracts anti-proliferative signals from outside. HPV16 E7 can directly interfere with transforming growth factor-β (TGF-β) signalling by binding to Smad proteins mediating growth arrest. It has been speculated that this property of HPV16 E7 contributes to HPV-associated carcinogenesis. Here, we show that E7 proteins from different low- and high-risk HPV types bind to Smad 1 to 4. The E7 protein from HPV1, a low-risk HPV causing plantar warts, efficiently inhibited Smad 3-induced transcription. Our data strongly indicate that the Smad-binding capacity of E7 proteins from different HPVs may preserve keratinocyte proliferation required for the productive viral life cycle rather than promoting carcinogenesis.


Archive | 2003

Container with at least one electrode

Herbert Müller-Hartmann; Michael Habig; Peter Hoffmann; Gregor Siebenkotten


Archive | 2005

Container and device for generating electric fields in different chambers

Herbert Müller-Hartmann; Michael Habig


Archive | 2009

Apparatus for automatically performing analyses

Edgar Dieβel; Ingmar Dorn; Michael Habig; Mike Küster; Klaus Ochmann


Archive | 2004

Vessel and device for generating electric fields in independent reaction spaces

Herbert Müller-Hartmann; Michael Habig


Archive | 2006

Method for treating small volumes with electrical current

Herbert Mueller-Hartmann; Michael Habig


Archive | 2003

Behälter mit zumindest einer elektrode

Michael Habig; Peter Hoffmann; Herbert Müller-Hartmann; Gregor Siebenkotten


Biophysical Journal | 2010

Ion Channel Reconstitution on a Pore-Suspending Membrane on Microstructured Glass Chip: Towards Artificial Gap Junction Formation Between Bilayers and Cells

Mohamed Kreir; Christoph Methfessel; Michael Habig; Mathias Winterhalter; Niels Fertig


Archive | 2009

Device for proving biochemical activity of membrane bodies

Michael Habig; Christoph Methfessel

Collaboration


Dive into the Michael Habig's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge